Source: Eur Respir J 2011; 37: 59-69
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Wilschanski M., Miller L.L., Shoseyov D., Blau H., Rivlin J., Aviram M., Cohen M., Armoni S., Yaakov Y., Pugatch T., Cohen-Cymberknoh M., Miller N.L., Reha A., Northcutt V.J., Hirawat S., Donnelly K., Elfring G.L., Ajayi T., Kerem E.. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011; 37: 59-69

Member's Comments

No comment yet.

Related content which might interest you: Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation Source: Eur Respir Rev 2013; 22: 66-71 Year: 2013 Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013 Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients Source: Eur Respir J 2004; 23: 679-684 Year: 2004 Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient Source: Eur Respir J 2002; 19: 374-376 Year: 2002 Atypical cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=38 Year: 2006 A novel CFTR mutation found in a Chinese cystic fibrosis patient Source: Eur Respir J 2005; 26: Suppl. 49, 402s Year: 2005 High morbidity and mortality in cystic fibrosis patients compound heterozygous for 3905insT and ΔF508 Source: Eur Respir J 2001; 17: 1181-1186 Year: 2001 Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis Source: Annual Congress 2013 –Cystic fibrosis: lung function and change of lung function in infants and children before and after treatment Year: 2013 Topical application of gentamicin causes a reduction of sweat ion concentration in cystic fibrosis patients carrying nonsense mutations Source: Eur Respir J 2001; 18: Suppl. 33, 9s Year: 2001 Cystic fibrosis transmembrane conductance regulator pharmacotherapy Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=88 Year: 2006 Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Gene therapy for cystic fibrosis: successes and challenges Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=79 Year: 2006 Pharmacological treatment of the biochemical defect in cystic fibrosis airways Source: Eur Respir J 2001; 17: 1314-1321 Year: 2001 Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator (CFTR) ion transport Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function Source: Eur Respir J 2011; 37: 1076-1082 Year: 2011 Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID) Source: Breathe, 17 (3) 210088; 10.1183/20734735.0088-2021 Year: 2021 CFTR gene mutations detected in Japanese individuals with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 716s Year: 2006 Evaluation of MRP1-5 gene expression in cystic fibrosis patients homozygous for the ΔF508 mutation Source: Annual Congress 2003 - Cystic fibrosis: new genes, new controversies Year: 2003 The impact of genotype on clinical course of cystic fibrosis (CF) in adult patients Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013